ARMP vs INNV

For growth investors, Armata Pharmaceuticals, Inc.

(ARMP) is the stronger pick with 14. 2% revenue growth year-over-year, versus 11. 8% for InnovAge Holding Corp. (INNV). Analysts rate Armata Pharmaceuticals, Inc. (ARMP) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Armata Pharmaceuticals, Inc.

(ARMP) delivered a total return of +119. 4%, compared to -68. 5% for InnovAge Holding Corp. (INNV). Over 10 years, the gap is even starker: INNV returned -68. 7% versus ARMP's -97. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Armata Pharmaceuticals, Inc.

(ARMP) is the lower-risk stock at 1. 24β versus InnovAge Holding Corp. 's 1. 49β — meaning INNV is approximately 19% more volatile than ARMP relative to the S&P 500.

By revenue growth (latest reported year), Armata Pharmaceuticals, Inc.

(ARMP) is pulling ahead at 14. 2% versus 11. 8% for InnovAge Holding Corp. (INNV). On earnings-per-share growth, the picture is similar: Armata Pharmaceuticals, Inc. grew EPS 72. 6% year-over-year, compared to -37. 5% for InnovAge Holding Corp.. Over a 3-year CAGR, INNV leads at 6. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

InnovAge Holding Corp.

(INNV) is the more profitable company, earning -3. 6% net margin versus -365. 6% for Armata Pharmaceuticals, Inc. — meaning it keeps -3. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INNV leads at -3. 5% versus -820. 2% for ARMP. At the gross margin level — before operating expenses — INNV leads at 68. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ARMP: 63.

9% to $15. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Armata Pharmaceuticals, Inc.

(ARMP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 24)). Both have compounded well over 10 years (ARMP: -97. 6%, INNV: -68. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.